ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 0 | – | 0.00% | – |
| Q2 2023 | $0 | – | 0 | – | 0.00% | – |
| Q1 2023 | $0 | – | 0 | – | 0.00% | – |
| Q4 2022 | $0 | – | 0 | – | 0.00% | – |
| Q3 2022 | $0 | – | 0 | – | 0.00% | – |
| Q2 2022 | $0 | – | 0 | – | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q4 2021 | $1,000 | -98.3% | 7 | -98.1% | 0.00% | -100.0% |
| Q3 2021 | $59,000 | +5.4% | 371 | -13.5% | 0.00% | 0.0% |
| Q2 2021 | $56,000 | +3.7% | 429 | +2.9% | 0.00% | 0.0% |
| Q1 2021 | $54,000 | -6.9% | 417 | +20.9% | 0.00% | 0.0% |
| Q4 2020 | $58,000 | +34.9% | 345 | +23.2% | 0.00% | 0.0% |
| Q3 2020 | $43,000 | +72.0% | 280 | +67.7% | 0.00% | +100.0% |
| Q2 2020 | $25,000 | – | 167 | – | 0.00% | – |
| Q1 2020 | $0 | – | 0 | – | 0.00% | – |
| Q4 2019 | $0 | – | 0 | – | 0.00% | – |
| Q3 2019 | $0 | – | 0 | – | 0.00% | – |
| Q2 2019 | $0 | – | 0 | – | 0.00% | – |
| Q1 2019 | $0 | – | 0 | – | 0.00% | – |
| Q4 2018 | $0 | – | 0 | – | 0.00% | – |
| Q3 2018 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |